It's Time For Novartis To Put Its Leqvio Launch Strategy To The Test
Executive Summary
Novartis Pharmaceuticals US head Victor Bulto talks to Scrip about the launch of Leqvio; the cholesterol-lowering medicine now approved by the US FDA.
You may also be interested in...
A Look At Leqvio’s Lacklustre Launch
The Swiss major’s CFO Harry Kirsch told Scrip that US cardiologists are slowly but surely getting to grips with the 'buy-and-bill' reimbursement model for Leqvio, while EU sales are not going to grow significantly until cardiovascular outcomes data read out in a few years’ time.
Novartis Gets Expansion For Earlier Use Of Leqvio
Leqvio was approved by the US FDA for a broad label for high cholesterol in patients with an increased risk of heart disease, expanding beyond the initial approval for patients with ASCVD.
AstraZeneca Pulls Plug On Ionis’ PCSK9 Candidate
While the Phase IIb SOLANO trial of ION449 met its primary endpoint, AstraZeneca had set a high bar of 70% LDL cholesterol reduction for competitiveness that the study did not hit.